{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:55:44Z","timestamp":1762624544307,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background<\/jats:bold>: Ticagrelor monotherapy after 3 months dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI). However, the impact of this approach among the patient with diabetes remains unknown.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold>: This was a sub-analysis of the Ticagrelor Monotherapy after 3 months in the Patients Treated with New Generation Sirolimus Eluting Stent for Acute Coronary Syndrome (TICO) trial. After successful PCI, the patients were randomly assigned to ticagrelor monotherapy after 3-months DPAT or to ticagrelor-based 12-months DAPT. We compared ischemic events and bleeding events between the patients with diabetes and without diabetes for 12 months. Ischemic events were defined as death, myocardial infarction, ischemic stroke, transient ischemic attack, stent thrombosis, and any revascularizations. Bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria and Bleeding Academic Research Consortium (BARC) definition.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold>: Between August 2015 and October 2018, 3,056 patients were enrolled in the TICO trial, of which 835 (27.3%) had diabetes mellitus. Diabetes mellitus was associated with all evaluated ischemic and bleeding events. No significant differences in any ischemic events were observed in patients with diabetes between ticagrelor monotherapy after 3-months DAPT and ticagrelor-based 12-months DAPT (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.45\u20131.52, p = 0.540). In patients with diabetes, the overall incidence of bleeding complications during the 12-months follow-up period did not differ between the two treatment groups (HR 0.83, 95% CI 1.48\u20131.43, p = 0.505). However, ticagrelor monotherapy was significantly reduced both any TIMI bleeding and BARC three or five bleeding events in diabetes patients in the 3-months landmark analysis, after 3-months DAPT period (HR 0.20, 95% CI 0.07\u20130.59, p = 0.003).<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold>: In diabetic patients, ticagrelor monotherapy showed a lower incidence of bleeding complications after 3-months DAPT period, without increasing ischemic complications, compared with ticagrelor-based 12-months DAPT (ClinicalTrials.gov Identifier: NCT02494895).<\/jats:p>","DOI":"10.3389\/fphar.2020.620906","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T20:29:51Z","timestamp":1610656191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Kyeong Ho","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Yul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Jae","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong Keuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Kyu","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the TICO Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J. Am. Coll. Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e5170","DOI":"10.1136\/bmj.e5170","article-title":"Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials","volume":"345","author":"Bangalore","year":"2012","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jacc.2015.05.085","article-title":"Meta-analyses of dual antiplatelet therapy following drug-eluting stent implantation: do bleeding and stent thrombosis weigh similar on mortality?","volume":"66","author":"Capodanno","year":"2015","journal-title":"J. Am. Coll. Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur. Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4093\/dmj.2015.39.2.95","article-title":"Current antiplatelet treatment strategy in patients with diabetes mellitus","volume":"39","author":"Jung","year":"2015","journal-title":"Diabetes Metab. J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.jacc.2014.01.064","article-title":"Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials","volume":"63","author":"Kedhi","year":"2014","journal-title":"J. Am. Coll. Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"J. Am. Med. Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ahj.2019.02.015","article-title":"Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design","volume":"212","author":"Kim","year":"2019","journal-title":"Am. Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jacc.2016.11.045","article-title":"Proposed standardized neurological endpoints for cardiovascular clinical trials: an academic research Consortium initiative","volume":"69","author":"Lansky","year":"2017","journal-title":"J. Am. Coll. Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline Focused\u00a0Update on duration of Dual Antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology\/American Heart association Task\u00a0Force\u00a0on\u00a0Clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J. Am. Coll. Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prostaglandins.2015.05.002","article-title":"Platelets and diabetes mellitus","volume":"120","author":"Santilli","year":"2015","journal-title":"Prostag. Other Lipid Mediat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.pcad.2017.12.003","article-title":"Duration of dual antiplatelet therapy following drug-eluting stent implantation in diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Sharma","year":"2018","journal-title":"Prog. Cardiovasc. Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1161\/01.cir.96.6.1761","article-title":"Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI)","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0735-1097(02)01971-x","article-title":"Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients","volume":"40","author":"Van Belle","year":"2002","journal-title":"J. Am. Coll. Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"J. Am. Med. Assoc"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.620906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T13:07:57Z","timestamp":1610716077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.620906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":23,"alternative-id":["10.3389\/fphar.2020.620906"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.620906","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"article-number":"620906"}}